Open AccessASPERGILLOSIS
Author(s) -
Javaria Rasheed,
Rushan Hassan,
Muhammad Usman Khalid,
Fauzia Zafar
Publication year - 2018
Publication title -
the professional medical journal/the professional medical journal
Language(s) - English
Resource type - Journals
eISSN - 2071-7733
pISSN - 1024-8919
DOI - 10.29309/tpmj/2018.25.06.290
Subject(s) - allergic bronchopulmonary aspergillosis , medicine , itraconazole , cystic fibrosis , aspergillosis , asthma , aspergillus fumigatus , immunoglobulin e , lung disease , disease , immunology , pediatrics , lung , intensive care medicine , dermatology , antifungal , antibody
Allergic bronchopulmonary aspergillosis (ABPA) is an illness caused byhypersensitivity to colonized Aspergillus fumigatus, mostly involving susceptible adult patientswith history of asthma and cystic fibrosis. Timely given appropriate treatment can reduceclinical symptoms, decrease lung infiltrates and stop progression to chronic lung disease. Inliterature review, treatment strategies used in ABPA children are limited. Herein we present acase of 10-year old asthmatic girl who, on developing ABPA, was successfully treated by theuse of low dose corticosteroids combined with itraconazole for 3 months duration. We suggestthat in financial constraint circumstances, ABPA in children can be successfully treated withoutanti-IgE therapy.